Acasti Pharma, Inc (ACST)

[dave86]

Doug Loe, PhD, the biotech analyst at US-based EuroPacific Securities, raised his 1-year target on Acasti from $4.75 to $6.75—because he saw the data as a significant risk-reduction event for Acasti, and therefore lowered the discount rate he uses to calculate Acasti’s NPV from 30% to 20%. (It’s worth noting that a reduction in the discount rate to 15% boosts Acasti’s NPV to $10.78/share; I would expect events that will allow Doug to reduce his discount rate to 15% to occur in the next 4-6 months.)